Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + trametinib in advanced solid tumors, pancreatic cancer, and KRAS-mutant colorectal cancer
NL-OMON47396Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ribociclib and trametinib in pancreatic adenocarcinoma (PDAC), colorectal cancer (CRC) and Nonhematologic neoplasms, sponsored by Novartis. Primary endpoints: Maximum tolerated dose, Recommended Phase 2 regimen and 1 more. Started Jul 2016; status: active, not recruiting.
02
Drugs
ribociclibtrametinib
03
Conditions
pancreatic adenocarcinoma (PDAC)colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON47396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47396.